Amarantus Bioscience Holdings’ (OTCQB:AMBS) master services agreement with the lab services arm of ICON (NASDAQ:ICLR) puts Amarantus on the road to commercializing its LymPro diagnostic blood test for the early detection of Alzheimer’s disease (AD)…..
See BT for rest of today's feature article on AMBS
Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke patients, with data to be released before year end.
“If we get the results we’re looking for, this could have a dramatic impact on stroke medicine and greatly improve treatment for more severe stroke patients,” chairman and CEO, Gil Van Bokkelen, says in an interview with BioTuesdays
Cleveland-based Athersys is developing MultiStem for the treatment of conditions in the cardiovascular, neurological, inflammatory and immune disease areas.
MultiStem is a biologic product manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. The stem cell product can be expanded on a large scale for future use and stored in frozen form until needed....
See BioTuesdays for rest of this week's feature article on ATHX